Leslie A. Andritsos
Expertise in
24
conditions

Dr. Leslie A. Andritsos

Hematology
University Of New Mexico Ems Consortium
1 University Of New Mexico, 
Albuquerque, NM 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
27 Years of Experience
Expertise in
24
conditions
University Of New Mexico Ems Consortium
1 University Of New Mexico, 
Albuquerque, NM 

Overview

Leslie Andritsos is a Hematologist practicing medicine in Albuquerque, New Mexico. She has been practicing medicine for over 27 years.

Dr. Andritsos is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Hairy Cell Leukemia (HCL), Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Splenectomy.

She is actively involved in clinical research, co-authoring 108 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Unm Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

University of New Mexico Ems Consortium
1 University Of New Mexico, Albuquerque, NM 87131

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia
Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia
Enrollment Status: Recruiting
Publish Date: July 02, 2026
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine
Study Phase: Phase 3
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Lenalidomide, Anti-CD19 Monoclonal Antibody
Study Phase: Phase 2
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
View 8 Less Clinical Trials

108 Total Publications

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Journal: Blood
Published: January 05, 2026
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

New Mexico Cancer Center

4901 Lang Ave NE, 
Albuquerque, NM 
 (6.3 miles away)
505-842-8171
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Jose Avitia is a Hematologist practicing medicine in Albuquerque, New Mexico. Dr. Avitia is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Large-Cell Immunoblastic Lymphoma, Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML). Dr. Avitia is board certified in American Board Of Internal Medicine. Dr. Avitia is currently accepting new patients.

Expertise in
15
conditions
Dr. Matthew L. Fero
Hematology | Oncology
Expertise in
15
conditions
Dr. Matthew L. Fero
Hematology | Oncology
Referral may be required

University Of New Mexico Hospitals

2211 Lomas Blvd NE, 
Albuquerque, NM 
 (0.3 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Fero is a Hematologist and an Oncologist practicing medicine in Albuquerque, New Mexico. Dr. Fero is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Multiple Myeloma, Classical Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL).

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

UNM Medical Group Inc

Albuquerque, NM 
 (1.4 miles away)
505-272-4946
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Ian Rabinowitz is a Hematologist practicing medicine in Albuquerque, New Mexico. Dr. Rabinowitz is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Primary Lymphoma of the Brain, and Large-Cell Immunoblastic Lymphoma. Dr. Rabinowitz is currently accepting new patients.

Frequently Asked Questions about Dr. Leslie A. Andritsos

How do I make an appointment with Dr. Leslie A. Andritsos?

You can book an appointment with Dr. Leslie A. Andritsos by calling their office at 505-272-4946. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leslie A. Andritsos a top-rated expert for Hairy Cell Leukemia (HCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leslie A. Andritsos is classified as an Elite expert for Hairy Cell Leukemia (HCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leslie A. Andritsos specialize in?

While Dr. Leslie A. Andritsos is a Hematology, they have specific expertise in Hairy Cell Leukemia (HCL), Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Leslie A. Andritsos participate in research or clinical trials?

Yes. Dr. Leslie A. Andritsos has published 108 articles and abstracts on conditions like Hairy Cell Leukemia (HCL). You can view a list of Dr. Leslie A. Andritsos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Leslie A. Andritsos accept my insurance?

Dr. Leslie A. Andritsos accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 505-272-4946 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andritsos's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile